RBC Capital Reiterates Sector Perform on Beam Therapeutics, Maintains $27 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has reiterated a Sector Perform rating on Beam Therapeutics (NASDAQ:BEAM) and maintained a $27 price target.
August 07, 2024 | 3:36 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital analyst Luca Issi has reiterated a Sector Perform rating on Beam Therapeutics and maintained a $27 price target.
The reiteration of a Sector Perform rating and maintenance of the price target at $27 suggests that RBC Capital sees no immediate upside or downside potential for Beam Therapeutics. This is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100